This short article describes how Organovo is using a novel technology called bioprinting to produce liver and kidney tissues that could help reshape the way drugs are tested and organs are transplanted in our days. It also discusses the challenges and potential effects on society.
3D printing technology has made significant advancements in the past few years. Can 3D printing be used in orthopaedics? Is this technology ready for surgery? How could orthopaedic practices best position themselves?
Additive manufacturing – also known as 3D-printing – has gained significant traction in commercial industries. In the medical community, there is promise of applying additive manufacturing techniques to tissue engineering, with the hope of developing replacement organs, ending the current unsatisfiable demand for transplants.
Organovo is a company developing 3D-bioprinted products for pharmacologic research and development, with a longer-term goal of developing printed tissue platforms. But is there truly a need for 3D-bioprinted products in this space? And is the idea of a 3D-printed organ merely a pipe dream?
Can open innovation speed the drug discovery pipeline?
Prellis Biologics' holographic 3D printing of biomaterial and ethical considerations surrounding manufactured organs.
3D printing is poised to revolutionize supply chains in life sciences. Medical device and pharma giants are preparing to leverage this new technology to deliver customized medical implants with localized, just-in-time (JIT) manufacturing.
Put down that pipette! Transcriptic is turning the costs structure of biotechnology on its head and making experimental results more reliable by using standardized, coded protocols and automated lab equipment.
Monsanto is currently battling crop yield performance and the public's disdain for GMOs. Can Monsanto overcome the challenges it faces to become a leader for the agricultural industry in driving performance and reducing the overall carbon footprint.
PTT, the Thai National Oil Company, an obvious candidate to blame for the global climate change situation is using a not-so-obvious strategy to mitigate the effects of climate change and drive the company into a new age in the process.
The leather industry faces immense regulatory pressure while new players are leveraging breakthroughs in biotechnology.